MELD-Na Score

If result > 10, check result (adjusted)

MELD‑Na Score: Estimates short‑term mortality risk in advanced liver disease using bilirubin, creatinine, INR, and serum sodium 1 [Level II evidence].

mg/dLumol/L
mg/dLumol/L
mEq/Lmmol/L

Indications for Use

Used to predict short‑term mortality in cirrhosis and prioritize liver‑transplant allocation, especially when hyponatremia increases risk. Incorporating sodium improves 90‑day waitlist mortality prediction and reduces deaths compared with MELD alone 1 [Level I evidence]; validated in large cohorts with reduced waitlist mortality after adoption 2 [Level I evidence]. Also helps stratify decompensation severity and guide timing of transplant evaluation.

Insights & Cautions

Underestimates mortality in hyponatremia and misses severity in ACLF, where 90‑day mortality is systematically underpredicted 1. Hyponatremic patients gain improved prioritization after Na incorporation, yet residual risk persists at low MELD‑Na 2. Sex disparity remains: women have lower transplant rates at identical MELD‑Na 3. Performs well overall but is surpassed by MELD 3.0, which improves discrimination and reduces sex bias 4.